Buradasınız

Anasayfa » Content

Sürekli Ayaktan Periton Diyalizi Uygulanan Hastalarda Koroner Arter Hastalığı Risk Faktörleri

Coronary Artery Disease Risk Factors in Patients on Continuous Ambulatory Peritoneal Dialysis

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Aim: We aimed to investigate especially early stage non tradi¬tional cardiovascular risk factors in end stage renal failure patients who were in Continued Ambulatory Peritoneal Dialysis (CAPD) pro¬gramme in our center. Methods: In this study 21 CAPD patients and 21 sex and age matched controls were enrolled. The clinical history and demographic parameters were obtained and than for physical evaluation blood samples were drawn for 12 hours fasting glucose, serum total cholesterol, HDL- cholesterol, LDL- cholesterol, triglyceride, apoA, apoB, total protein, albumin, calcium, phosphorus, parathormon (PTH), hemoglobin (Hb), Lp(a), C-reactive protein (CRP), homocysteine (tHcy), anticardiolipin antibody (ACLA), fibrinogen. Results: While age, sex, Body Mass Index (BMI), smoking status and hereditary factors were comparable between the groups, diabetes mellitus and hypertension were significantly higher in CAPD patients. There was no statistical significance between the groups considering mean serum total cholesterol, HDL- cholesterol, LDL-cholesterol, triglyceride, PTH, Lp(a), tHcy, ACLA Ig M and ACLA Ig G levels. In the present study mean apoA level was significantly lower in the study group, while apoB and phosphorus were higher (p=0.003). Also mean total protein, albumin, calcium, and Hb level were significantly lower, while mean CRP and fibrinogen were high¬er in the study group (p=0.0003). Conclusion: Because of the high rates of increased risk factors for coronary artery disease in CAPD patients at early stages, these patients should be closely followed for coronary artery disease.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu çalışmada merkezimizde son dönem böbrek yetmezliği tanısı konularak sürekli ayaktan periton diyalizi (SAPD) uyguladığımız hastalarımızdaki özellikle geleneksel olmayan kardiyovaskü-ler risk faktörlerini erken dönemde araştırmayı amaçladık. Materyal ve Metod: Çalışmaya 21 SAPD hastası ile kontrol grubu olarak yaş ve cinsiyetleri uyumlu 21 sağlıklı birey alındı. Olguların demografik özellikleri ve anamnezleri alındıktan sonra fizik muayeneleri yapıldı. 12 saatlik açlık sonrası açlık kan şekeri, serum total kolesterol, HDL-kolesterol, LDL-kolesterol, trigliserit, apoA, apoB, total protein, albümin, kalsiyum, fosfor, parathormon (PTH), hemoglobin (Hb), Lp(a), C-reaktif protein (CRP), homosistein (tHcy), antikardiyolipin antikorları (ACLA), fibrinojen için kan örneği alındı. Bulgular: Gruplar arasında yaş, cinsiyet, vücut kitle indeksi (BMI) sigara içimi, heredite açısından fark bulunmazken, diabetes mellitus (DM) ve hipertansiyon (HT) SAPD hastalarında anlamlı olarak yüksek bulundu. Total kolesterol, HDL-kolesterol, LDL-kolesterol, trigliserit, PTH, Lp(a), tHcy, ACLA IgM ve IgG'nin ortalama değerleri arasında istatistiksel olarak anlamlı fark bulunmadı. Çalışmamızda apoA'nın düşüklüğü, apoB ve fosforun yüksekliği istatistiksel olarak anlamlıydı (p=0.03). Ortalama total protein, albümin, kalsiyum, Hb'nin düşüklüğü, CRP ve fibrinojenin yüksekliği kontrol grubuna göre istatistiksel olarak anlamlı bulundu (p=0.0003). Sonuç: SAPD olgularının erken dönemde yüksek KAH risk faktörleri ile karşı karşıya olması nedeniyle, KAH açısından yakın takibi gerekmektedir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_17_pp_106-112.pdf
  • 3
106-112
  • Turkish

REFERENCES

References: 

1. DOQ1 and NKF. Chronic Kidney Disease as a public health problem. Am J Kidney Dis 2002;39:17-31.
2. Rattazzi M, Puato M, Faggin E, et al. New markers of accelerated atherosclerosis in end-stage renal disease. J
Nephrol 2003;16:11-20.
3. Sarnak MJ. Cardiovascular complications in chronic kidney
disease. Am J Kidney Dis 2003;41:S11-S17.
4. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risk in chronic hemodialysis patient. Kidney Int 2000;58:353-362.
5.
Emi
n Yılmaz ME, Kara IH, Alan S. Hemodiyaliz hastalarında kardiyovasküler mortalite ve diğer risk faktörlerinin değerlendirilmesi. Dicle Tıp Dergisi 2001;28:151-161.
6. Eikelboom JW,
Hanke
y GJ. Associations of homocysteine, C-rective protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001;10:377-383.
7. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis
patients. Kidney Int 1999;55:648-658.
8. Murphy SW, Foley RN, Parfey PJ. National kidney foundation task force on cardiovascular disease:screening and treatment for cardiovascular disease in patients with chronic renal
disease. Am J Kidney Dis 1998;32:184-199.
9. Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann
Intern Med 1998;129:457-461.
10.
Kronenber
g F, Utermann G, Dieplinger H. Lipoprotein (a) in renal disease. Am J Kidney Dis 1996;27:1-25.
11. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: Meta-analysis of Prospective Studies.
Circulation 200;102:1082-1085.
12. Dieghan CJ, Caslake MJ, McConnell M, et al. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
111
0 Coronary Artery Disease Risk Factors in Patients on Continuous Ambulatory Peritoneal Dialysis
extend of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852-862.
13. Asmann G, Schulte H. Resuits and conclusions of the Prospective Cardiovascular Munster (PROCAM) Study in: G. Assmann (ed). Lipid Metabolism Disorders and Coronary Heart Disease. München, MMV Medizin Verlag, 1989;p:96.
14. McLean JW, Tomlinson JE, Lawn RM, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-137.
15. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. JAMA 1996;276:544-548.
16. Mahley RW, Weisgraber KH, Innerarity TL, Rall SC. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA
1991;265:78-83.
17. Gordon DJ, Probstfield JL, Garrison RJ, et al. HDL cholesterol and cardiovascular disease. Four prospective American
studies. Circulation 1989;79:8-15.
18. Webb AT, Reaveley DA, O'Donnell M, et al. Lipoprotein (a) in patients on maintanance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant
1993;8:609-613.
19. Siamopoulos KC, Elisaf MS, Bairaktari HT, et al. Lipid parameters including lipoprotein (a) in patients undergoing
CAPD and hemodialysis. Perit Dial Int 1995;15:342-347.
20. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A
quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing
folic acid intakes. JAMA 1995;274:1049-1057.
21. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-232.
22. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood
levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000;160:422-434.
23. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic
renal disease. J Am Soc Nephrol 1999;10:891-900.
24. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous
endothelial cells. Blood 1990;75:895-901.
25. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM.
Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial
cells. Arterioscler Thromb 1993;13:1327-1333.
26. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-2879.
27. Von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of
homocyst(e)inemia as a cardiovascular risk factor in men.
Arterioscler Thromb 1994;14:460-464.
28. Moustapha A, Gupta A, Robinson K, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and
peritoneal dialysis. Kidney Int 1999;55:1470-1475.
29. Nadir I, Duman N. Kronik böbrek yetmezliği ve hiperhomosisteinemi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1999;2:46-50.
30. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective
study. Arterioscler Thromb Vasc Biol 1997;17:2554-2558.
31. Shemin D, Lapane KL, Bausserman L, et al. Plasma total homocysteine and hemodialysis access thrombosis: a
prospective study. J Am Soc Nephrol 1999;10:1095-1099.
32. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation and atherosclerosis in
chronic renal failure. Kidney Int 1999;55:1899-1911.
33. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
34.
Yakupoğl
u G, Süleymanlar G, Özmen T, Sapan M, Ersoy FF. Kompanse kronik böbrek yetmezlikli hastalarda serum lipoprotein (a) düzeyi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1996;1:11-15.
35. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int
1998;54:627-636.
36. Chung SH, Heimbürger O, Stenvinkel P, Bergström J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant
2001;16:2240-2245.
37. Venkaia Seshan S, Barisoni L, Smith S, et al. Renal disease in antiphospholipid syndrome. J Am Soc Nephrol 1996;7:1343.
38. Sonpal GM, Sharma A, Miller A. Primary antiphospholipid antibody syndrome, renal infarction and hypertension. J
Rheumatol 1993; 20:1221-1223.
39. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern
Med 1990;112:682-698.
40. Tsai RT, Wang CR, Lee GL, et al. Anticardiolipin antibodies in patients with acute myocardial infarction. Zhi 1991;24:213-220.
41. Hörkkö S, Miller E, Dudl E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized
phospholipids. J Clin Invest 1996;98:815-825.
42. Tsakiris DA, Marbet GA, Burkart F, Duckert F. Anticardiolipin antibodies and coronary heart disease. Eur Heart J.
1992;13(12):1645-1648.

Thank you for copying data from http://www.arastirmax.com